Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Cancer, Liver Cancer, Primary Liver Cancer, Hepatocellular Carcinoma, Hepatoma

In brief

The purpose of this study is to determine if PI-88 is effective and safe in patients who have had surgery to remove primary liver cancer.

Key facts

Study ID

NCT00568308

Run by

Progen Pharmaceuticals

People needed

600

Starts

2007-12-01

Expected to finish

2008-07-01

Last updated by the study team

2011-06-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — United States of America, New York, United States
• Study site — Australia, Australia
• Study site — Canada, Canada
• Study site — Hong Kong, Hong Kong
• Study site — Italy, Italy
• Study site — Malaysia, Malaysia
• Study site — Singapore, Singapore
• Study site — Spain, Spain
• Study site — Dawan, Taiwan
• Study site — Thailand, Thailand

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.